These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 26991517)

  • 21. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
    Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
    Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults.
    Ma JD; Nafziger AN; Villano SA; Gaedigk A; Bertino JS
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1130-5. PubMed ID: 16569820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
    Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
    Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
    Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
    J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects.
    Greene SA; Kwak C; Kamin M; Vernillet L; Glenn KJ; Gabriel L; Kim HW
    Clin Transl Sci; 2022 Apr; 15(4):899-911. PubMed ID: 34877801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers.
    Doroshyenko O; Rokitta D; Zadoyan G; Klement S; Schläfke S; Dienel A; Gramatté T; Lück H; Fuhr U
    Drug Metab Dispos; 2013 May; 41(5):987-93. PubMed ID: 23401474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
    Stemkens R; Jager Vd; Dawson R; Diacon AH; Narunsky K; Padayachee SD; Boeree MJ; van Beek SW; Colbers A; Coenen MJH; Svensson EM; Fuhr U; Phillips PPJ; Te Brake LHM; Aarnoutse RE;
    Antimicrob Agents Chemother; 2023 Oct; 67(10):e0068323. PubMed ID: 37768317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.
    Tran JQ; Othman AA; Mikulskis A; Wolstencroft P; Elkins J
    Clin Pharmacol; 2016; 8():9-13. PubMed ID: 26929672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Rolapitant Administered Intravenously on the Pharmacokinetics of a Modified Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan) in Healthy Subjects.
    Wang X; Zhang ZY; Arora S; Wang J; Lu S; Powers D; Kansra V
    J Clin Pharmacol; 2018 Aug; 58(8):1074-1083. PubMed ID: 29693712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail.
    Johnson BM; Song IH; Adkison KK; Borland J; Fang L; Lou Y; Berrey MM; Nafziger AN; Piscitelli SC; Bertino JS
    J Clin Pharmacol; 2006 May; 46(5):577-87. PubMed ID: 16638741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.
    Wang J; Zhang ZY; Lu S; Powers D; Kansra V; Wang X
    Support Care Cancer; 2019 Mar; 27(3):819-827. PubMed ID: 30084103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.
    Morcos PN; Chang L; Kulkarni R; Giraudon M; Shulman N; Brennan BJ; Smith PF; Tran JQ
    Eur J Clin Pharmacol; 2013 Nov; 69(11):1939-49. PubMed ID: 23872824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
    Goh BC; Reddy NJ; Dandamudi UB; Laubscher KH; Peckham T; Hodge JP; Suttle AB; Arumugham T; Xu Y; Xu CF; Lager J; Dar MM; Lewis LD
    Clin Pharmacol Ther; 2010 Nov; 88(5):652-9. PubMed ID: 20881954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Comprehensive In Vivo and In Vitro Assessment of the Drug Interaction Potential of Red Ginseng.
    Seong SJ; Kang WY; Heo JK; Jo J; Choi WG; Liu KH; Lee S; Choi MK; Han YH; Lee HS; Ohk B; Lee HW; Song IS; Yoon YR
    Clin Ther; 2018 Aug; 40(8):1322-1337. PubMed ID: 30078466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitory effects of kale ingestion on metabolism by cytochrome P450 enzymes in rats.
    Yamasaki I; Yamada M; Uotsu N; Teramoto S; Takayanagi R; Yamada Y
    Biomed Res; 2012; 33(4):235-42. PubMed ID: 22975634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.
    Nordmark A; Andersson A; Baranczewski P; Wanag E; Ståhle L
    Eur J Clin Pharmacol; 2014 Feb; 70(2):167-78. PubMed ID: 24186263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.
    Rowland A; van Dyk M; Warncken D; Mangoni AA; Sorich MJ; Rowland A
    Br J Clin Pharmacol; 2018 Mar; 84(3):501-509. PubMed ID: 29178272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.
    Blakey GE; Lockton JA; Perrett J; Norwood P; Russell M; Aherne Z; Plume J
    Br J Clin Pharmacol; 2004 Feb; 57(2):162-9. PubMed ID: 14748815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects.
    Edwards JE; Eliot L; Parkinson A; Karan S; MacConell L
    Adv Ther; 2017 Sep; 34(9):2120-2138. PubMed ID: 28808886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.
    Dumond JB; Vourvahis M; Rezk NL; Patterson KB; Tien HC; White N; Jennings SH; Choi SO; Li J; Wagner MJ; La-Beck NM; Drulak M; Sabo JP; Castles MA; Macgregor TR; Kashuba AD
    Clin Pharmacol Ther; 2010 Jun; 87(6):735-42. PubMed ID: 20147896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.